Portage Biotech (NASDAQ:PRTG) posted its quarterly earnings data on Monday. The company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03, MarketWatch Earnings reports.
Shares of NASDAQ PRTG opened at $16.99 on Wednesday. Portage Biotech has a twelve month low of $11.85 and a twelve month high of $44.98. The stock’s 50 day moving average price is $20.55 and its 200-day moving average price is $22.42.
Several equities analysts have recently issued reports on PRTG shares. Cantor Fitzgerald began coverage on Portage Biotech in a research note on Thursday, August 19th. They issued an “overweight” rating and a $35.00 price target on the stock. B. Riley started coverage on Portage Biotech in a report on Thursday, September 2nd. They set a “buy” rating and a $40.00 target price on the stock. Finally, Oppenheimer started coverage on Portage Biotech in a research note on Monday, September 20th. They issued an “outperform” rating and a $30.00 price objective on the stock.
About Portage Biotech
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.